Traduction de «ongoing in other diseases in which » (Néerlandais → Français) :

Trials are ongoing in other diseases in which IL-1 beta is believed to play an important role. Other diseases include refractory gout, chronic obstructive pulmonary disease (COPD), type 2 diabetes and systemic juvenile idiopathic arthritis (SJIA).
Des essais sont en cours dans d’autres maladies dans lesquelles IL-1β joue probablement un rôle important, telles que la goutte réfractaire, la broncho-pneumopathie chronique obstructive (BPCO), le diabète de type 2 et l’arthrite idiopathique juvénile systémique (AJIS).

Studies are ongoing in other diseases in which IL-1 beta plays an important role, such as some forms of gout – one of the most painful types of arthritis, COPD (Chronic Obstructive Pulmonary Disease), type 2 diabetes and systemic juvenile idiopathic arthritis.
Les études continuent dans d’autres maladies dans lesquelles IL-1 bêta joue un rôle important, telles que certaines formes de goutte, l’un des types d’arthrite les plus douloureux, la broncho-pneumopathie chronique obstructive (BPCO), le diabète de type 2 et l’arthrite idiopathique juvénile systémique.

Trials are also ongoing in other diseases in which IL-1 beta may play an important role, including type 2 diabetes and systemic juvenile idiopathic arthritis (SJIA).
Des essais sont en cours pour d’autres maladies dans lesquelles IL-1β joue probablement un rôle important, telles le diabète de type 2 et l’arthrite idiopathique juvénile systémique (AJIS).

These impacts however were more than offset by a number of positive factors, including: Marketing & Sales costs, which were lower by 0.4 percentage points due to productivity improvements partly offset by investments in growth areas; R&D costs, which decreased (improving +1.2 percentage points) as productivity savings funded continued investment in the development of differentiated generics; General & Administration costs, which decreased (+1.1 percentage points) due to ongoing cost reduction measures; and Other Income and Expenses, which were positive at 0.5 percentage points due to lower legal fees.
Cependant, ces impacts ont été plus que compensés par un certain nombre de facteurs positifs, notamment: une baisse de 0,4 point de pourcentage des coûts de Marketing et vente due à des gains de productivité en partie contrebalancés par des investissements dans des domaines en pleine croissance; une diminution des coûts de Recherche et développement (amélioration +1,2 point), des gains de productivité servant à financer des investissements continus dans le développement de génériques différenciés; un abaissement des coûts d’Administration et frais généraux (+1,1 point) grâce à des mesures continues de réduction des coûts; une progression de 0,5 point d'Autres produits et charges suite à une baisse des frais juridiques.

“Pfizer’s commitments build on our ongoing efforts to fight neglected tropical diseases, which includes the work done through our support of the International Trachoma Initiative, by our colleagues who participate in our Global Health Fellows program, and through our participation in WIPO Re: Search -- a publicprivate consortium for sharing intellectual property and expertise with the global health research community to promote the development of new drugs, vaccines and diagnostics for the treatment of neglected tropical diseases, malaria and tuberculosis. “We are proud to be a part of this innovative effort to support a healthier world”.
“Pfizer’s commitments build on our ongoing efforts to fight neglected tropical diseases, which includes the work done through our support of the International Trachoma Initiative, by our colleagues who participate in our Global Health Fellows program, and through our participation in WIPO Re: Search -- a publicprivate consortium for sharing intellectual property and expertise with the global health research community to promote the development of new drugs, vaccines and diagnostics for the treatment of neglected tropical diseases, malaria and tuberculosis.

Trials in other diseases, including type 2 diabetes and systemic juvenile idiopathic arthritis (SJIA), are also ongoing.
Des essais sont en cours dans d’autres maladies, comprenant le diabète de type 2 et l’arthrite idiopathique juvénile systémique (AJIS).

The other classification system frequently used is the International Classification of Diseases, which deals with mental and behavioural disorders, 10 th revision, developed by the WHO and published in 1992.
L’autre système de classification couramment utilisé est la Classification Internationale des Maladies relative aux troubles mentaux et du comportement, 10 e révision, développée par l’OMS et publiée en 1992.